



2025 J.P. Morgan Healthcare Conference

Overview of Large, Mid and Small Pharmaceutical Companies

Day 1 Presentation on achievements, financial performance, and future plans.

1. **Alnylam Pharmaceuticals:** Focused on RNAi technologies, Alnylam reported significant growth and pipeline advancements, including positive Phase III data for Amvuttra in treating ATTR-CM. The company aims for a 40% revenue CAGR through 2025 and plans to launch Amvuttra in the US, Japan, and Germany in 2025.
2. **BioMarin Pharmaceuticals:** Celebrated revenue growth and outlined plans for expanding indications for Voxzogo and Palynziq. The company anticipates several top-line results in 2025 and aims to achieve large BioPharma peer profit margins by 2026.
3. **Bristol Myers Squibb:** Highlighted double-digit sales growth and the success of new brands like Cobenfy. The company plans to focus on newer assets to counter the impact of generics and aims for significant cost savings and reinvestment in growth initiatives.
4. **Incyte:** Reported revenue growth and regulatory submissions for several products. The company expects pivotal trial readouts and multiple product launches in 2025, positioning it for future growth.
5. **Moderna:** Emphasized its mRNA platform and reported significant sales from Spikevax. The company anticipates regulatory approvals and late-stage pipeline milestones in 2025, including a new COVID-19 vaccine and a combination flu/COVID-19 vaccine.
6. **Neurocrine Biosciences:** Focused on the success of Ingrezza and the recent launch of Crenessity. The company plans to invest heavily in RCD and aims to deliver a new medicine to the market every two years.



7. **Pfizer:** Reaffirmed revenue targets and highlighted the impact of the Inflation Reduction Act. The company plans to focus on oncology growth through its acquisition of Seagen and expects regulatory decisions for key products in 2025.
8. **Sarepta Therapeutics:** Reported strong revenue growth driven by ELEVIDYS and outlined plans for expanding its gene therapy and RNA-based platforms. The company aims for significant revenue growth and multiple data readouts in 2025.
9. **Teva Pharmaceutical:** Highlighted consecutive revenue growth and its Pivot to Growth strategy. The company focuses on innovative medicines and biosimilars, with key drugs like Austedo and Ajovy showing significant growth.
10. **Vertex Pharmaceuticals:** Focused on the approval of Alyftrek for cystic fibrosis and the development of suzetrigine for acute pain. The company plans to expand its renal franchise and manufacturing capacity for Casgevy.
11. **Ascendis Pharma:** Emphasized rapid revenue growth and the success of Skytrofa and Yorvipath. The company plans to expand its endocrinology portfolio and form significant partnerships.
12. **BridgeBio Pharma:** Highlighted clinical progress and the commercial potential of Attruby for ATTR-CM. The company expects pivotal data readouts and regulatory submissions in 2025.
13. **Cytokinetics:** Focused on the launch of aficamten and omecamtiv mecarbil for heart failure. The company aims to build relationships with payers and achieve market access for its products.
14. **Edgewise Therapeutics:** Reported progress in its muscle disease and cardiovascular disease pipeline. The company anticipates multiple data readouts and regulatory submissions in 2025.



15. **Inspire Medical Systems:** Highlighted revenue growth and the approval of the Inspire V neurostimulation system. The company plans to expand its sales territories and launch new products in 2025.
16. **Recursion Pharmaceuticals:** Emphasized its OS platform and oncology portfolio. The company plans to maximize the return on its business combination with Exscientia and achieve multiple milestones in 2025.
17. **Roivant Sciences:** Focused on the potential of IMVT-1402 and Brepocitinib. The company anticipates multiple registrational trials and a strong capital position to achieve its goals.
18. **SpringWorks Therapeutics:** Highlighted the success of Osgiveo and the development of mirdametinib. The company plans for international launches and additional trials in 2025.
19. **Viking Therapeutics:** Focused on the development of VK2735 for obesity and VK2809 for NASH. The company plans to initiate a Phase III program and achieve significant clinical milestones in 2025.
20. **Xenon Pharmaceuticals:** Emphasized the development of azetukalner for epilepsy and MDD. The company anticipates key data readouts and regulatory submissions in 2025.
21. **Intellia Therapeutics:** Highlighted its focus on NTLA-2002 and Nex-z for HAE and ATTR. The company plans to complete enrollment for its Phase III programs and prepare for regulatory submissions.
22. **Nuvation Bio:** Reported progress in its oncology pipeline, including the approval of Taletrectinib in China. The company anticipates a commercial launch in the US and further clinical advancements in 2025.